BioSpace News Archive

Fact.MR, Rockville: The ongoing research project on orthopedic footwear market undertaken by Fact.MR forecasts a relatively stable outlook for 2021.

The microplate instruments market is predicted to garner handsome revenue over the 2020 -2030 forecast period on the back of stupendous rise in demand from the pharmaceutical and biotechnology sectors.

Thyroid hormone is responsible for regulation of body metabolism and deficiency of this hormone is expected to result in several symptoms like slow metabolism, weight gain, impaired memory, irregular heartbeat, and tiredness.

The branch of science that deals with manufacturing medicines and pharmaceutical products based on biological origins is called biological therapeutics.

The global epigenetics market is expected to grow at a fast paced CAGR in the next few years, owing to factors such as extensive use in the research of developmental and disease process, and growing importance of Life Science.

The market for fill-finish manufacturing is gaining significant impetus across the world. The constant technological advancements in fill-finish products and the increasing uptake of prefilled syringes are boosting the growth in this market.

Versantis AG, a clinical-stage company developing novel therapies for orphan liver diseases, announced the appoint of seasoned pharmaceutical executive Christopher Seaton to its Board of Directors.

InnoCare Pharma, a leading biopharmaceutical company, announced that China National Medical Products Administration has approved the clinical trial of Bruton’s tyrosine kinase inhibitor orelabrutinib in combination with R-CHOP for previously untreated patients with mantle cell lymphoma.

PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vor Biopharma, has announced the pricing of its initial public offering (IPO) of 9,828,017 shares of common stock at a public offering price of $18.00 per share

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming virtual investor conferences.